Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 212

1.

Gait variability as digital biomarker of disease severity in Huntington's disease.

Gaßner H, Jensen D, Marxreiter F, Kletsch A, Bohlen S, Schubert R, Muratori LM, Eskofier B, Klucken J, Winkler J, Reilmann R, Kohl Z.

J Neurol. 2020 Feb 11. doi: 10.1007/s00415-020-09725-3. [Epub ahead of print]

PMID:
32048014
2.

Parkinsonism in Huntington's disease.

Reilmann R.

Int Rev Neurobiol. 2019;149:299-306. doi: 10.1016/bs.irn.2019.10.006. Epub 2019 Nov 21.

PMID:
31779817
3.

How to evaluate effects of occupational therapy - lessons learned from an exploratory randomized controlled trial.

Schaeffer E, Streich S, Wurster I, Schubert R, Reilmann R, Wolfram S, Berg D.

Parkinsonism Relat Disord. 2019 Oct;67:42-47. doi: 10.1016/j.parkreldis.2019.09.013. Epub 2019 Sep 19.

PMID:
31621606
4.

Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories.

Ross CA, Reilmann R, Cardoso F, McCusker EA, Testa CM, Stout JC, Leavitt BR, Pei Z, Landwehrmeyer B, Martinez A, Levey J, Srajer T, Bang J, Tabrizi SJ.

Mov Disord Clin Pract. 2019 Aug 23;6(7):541-546. doi: 10.1002/mdc3.12808. eCollection 2019 Sep. No abstract available.

PMID:
31538087
5.

Impaired Isometric Force Matching in Upper and Lower Limbs Revealed by Quantitative Motor Assessments in Huntington's Disease.

Medzech S, Sass C, Bohlen S, Lange HW, Koch R, Schubert R, Ringelstein EB, Reilmann R.

J Huntingtons Dis. 2019;8(4):483-492. doi: 10.3233/JHD-190354.

PMID:
31450507
6.

Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures.

Hohenfeld C, Dogan I, Schubert R, Didszun C, Schöls L, Synofzik M, Giordano IA, Klockgether T, Schulz JB, Reilmann R, Reetz K.

Cerebellum. 2019 Oct;18(5):896-909. doi: 10.1007/s12311-019-01073-x.

PMID:
31441004
7.

Association of CAG Repeats With Long-term Progression in Huntington Disease.

Langbehn DR, Stout JC, Gregory S, Mills JA, Durr A, Leavitt BR, Roos RAC, Long JD, Owen G, Johnson HJ, Borowsky B, Craufurd D, Reilmann R, Landwehrmeyer GB, Scahill RI, Tabrizi SJ; TRACK-HD and Track-On HD Groups.

JAMA Neurol. 2019 Aug 12. doi: 10.1001/jamaneurol.2019.2368. [Epub ahead of print]

PMID:
31403680
8.

International Guidelines for the Treatment of Huntington's Disease.

Bachoud-Lévi AC, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, Craufurd D, Reilmann R, De Michele G, Rae D, Squitieri F, Seppi K, Perrine C, Scherer-Gagou C, Audrey O, Verny C, Burgunder JM.

Front Neurol. 2019 Jul 3;10:710. doi: 10.3389/fneur.2019.00710. eCollection 2019.

9.

A Feasibility Study of Quantitative Motor Assessments in Children Using the Q-Motor Suite.

van der Plas E, Schubert R, Reilmann R, Nopoulos PC.

J Huntingtons Dis. 2019;8(3):333-338. doi: 10.3233/JHD-190353.

PMID:
31256146
10.

Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy.

Klehmet J, Beutner S, Hoffmann S, Dornauer M, Paul F, Reilmann R, Brandt AU, Meisel A.

BMC Neurol. 2019 Jun 8;19(1):118. doi: 10.1186/s12883-019-1339-x.

11.

Physical Activity and Exercise Outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month Trial Within Cohort Evaluation of a Physical Activity Intervention in People With Huntington Disease.

Drew CJG, Quinn L, Hamana K, Williams-Thomas R, Marsh L, Dimitropoulou P, Playle R, Griffin BA, Kelson M, Schubert R, Muratori L, Reilmann R, Rosser A, Busse M.

Phys Ther. 2019 Sep 1;99(9):1201-1210. doi: 10.1093/ptj/pzz075.

PMID:
31101920
12.

Biological Motion Perception in Huntington's Disease.

Matheis T, Evinger C, Schubert R, Mazzola S, Fels M, Kemper N, Reilmann R, Muratori L.

J Huntingtons Dis. 2019;8(3):311-321. doi: 10.3233/JHD-180337.

PMID:
31033464
13.

A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies.

Espay AJ, Hausdorff JM, Sánchez-Ferro Á, Klucken J, Merola A, Bonato P, Paul SS, Horak FB, Vizcarra JA, Mestre TA, Reilmann R, Nieuwboer A, Dorsey ER, Rochester L, Bloem BR, Maetzler W; Movement Disorder Society Task Force on Technology.

Mov Disord. 2019 May;34(5):657-663. doi: 10.1002/mds.27671. Epub 2019 Mar 22. Review.

PMID:
30901495
14.

The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age.

Vizcarra JA, Sánchez-Ferro Á, Maetzler W, Marsili L, Zavala L, Lang AE, Martinez-Martin P, Mestre TA, Reilmann R, Hausdorff JM, Dorsey ER, Paul SS, Dexheimer JW, Wissel BD, Fuller RLM, Bonato P, Tan AH, Bloem BR, Kopil C, Daeschler M, Bataille L, Kleiner G, Cedarbaum JM, Klucken J, Merola A, Goetz CG, Stebbins GT, Espay AJ; MDS Technology Task Force and the MDS Rating Scales Program Electronic Development Ad-Hoc Committee.

Mov Disord. 2019 May;34(5):676-681. doi: 10.1002/mds.27673. Epub 2019 Mar 22. No abstract available.

PMID:
30901492
15.

Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?

Quarrell OWJ, Nance MA, Nopoulos P, Reilmann R, Oosterloo M, Tabrizi SJ, Furby H, Saft C, Roos RAC, Squitieri F, Landwehrmeyer GB, Burgunder JM; Juvenile Huntington Disease Working Group of the European Huntington Disease Network.

Mov Disord. 2019 Apr;34(4):584-585. doi: 10.1002/mds.27640. Epub 2019 Feb 20. No abstract available.

PMID:
30788860
16.

Activity Behaviour of Minipigs Transgenic for the Huntington Gene.

Rieke L, Fels M, Schubert R, Habbel B, Matheis T, Schuldenzucker V, Kemper N, Reilmann R.

J Huntingtons Dis. 2019;8(1):23-31. doi: 10.3233/JHD-180325.

PMID:
30689591
17.

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.

Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators.

Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15.

PMID:
30563778
18.

Interrater Reliability of the Unified Huntington's Disease Rating Scale-Total Motor Score Certification.

Winder JY, Roos RAC, Burgunder JM, Marinus J, Reilmann R.

Mov Disord Clin Pract. 2018 Apr 15;5(3):290-295. doi: 10.1002/mdc3.12618. eCollection 2018 May-Jun.

19.

Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations.

Mestre TA, Forjaz MJ, Mahlknecht P, Cardoso F, Ferreira JJ, Reilmann R, Sampaio C, Goetz CG, Cubo E, Martinez-Martin P, Stebbins GT; Members of the Movement Disorder Society Committee on Rating Scales Development.

Mov Disord Clin Pract. 2018 Jan 3;5(2):111-117. doi: 10.1002/mdc3.12571. eCollection 2018 Mar-Apr.

20.

Quantitative Measurements of Motor Function in Alzheimer's Disease, Frontotemporal Dementia, and Dementia with Lewy Bodies: A Proof-of-Concept Study.

Jeppesen Kragh F, Bruun M, Budtz-Jørgensen E, Hjermind LE, Schubert R, Reilmann R, Nielsen JE, Hasselbalch SG.

Dement Geriatr Cogn Disord. 2018;46(3-4):168-179. doi: 10.1159/000492860. Epub 2018 Sep 26.

PMID:
30257254

Supplemental Content

Loading ...
Support Center